SGS Associates Inc. Announces the Appointment of Stephen G. Sudovar
as Executive Chairman & CEO of Ambrilia Biopharma

Montclair, New Jersey, April 18, 2007 – SGS Associates Inc., has announced today the appointment of Stephen G. Sudovar to Executive Chairman of the Board of Directors and CEO of Ambrilia Biopharma. As Executive Chairman and Chief Executive Officer Mr. Sudovar will oversee the day to day operations of the company in Montreal, Canada as well as Paris, France.

Ambrilia also announced today that it has agreed to issue 2,231,405 of its common shares to certain investors, almost all of them being current shareholders of Ambrilia, at a price of $2.42 per share for an aggregate consideration of $5.4 million. These investors are Turenne Capital Partenaires, Innoven Partenaires, OTC Asset Management, DHR Investissement and certain other investors. Turenne Capital Partenaires is an insider of the Corporation by virtue of its present control over 12.6% of the outstanding common shares of Ambrilia. This $5.4 million transaction is subject to usual conditions, including the approval of the TSX and applicable regulatory authorities and is scheduled to close no later than May 18, 2007. The issue price of $2.42 per share represents the volume weighted average price of Ambrilia's common share on the TSX for the five days ending on April 11, 2007, being the date on which Ambrillia
Informally came to terms with representatives of the above-mentioned investors.

"I believe Ambrilia is poised for success and I look forward in guiding the Company as it continues to make advances in its key programs such as the HIV Integrase Inhibitor, and particularly our productive relationship with Merck in the development of PPL-100. We also look forward to having new data available for our anti-cancer peptide, PCK3145, before the end of the second quarter” said Mr. Sudovar, Executive Chairman and CEO. Finally, I would like to acknowledge the vote of confidence from our shareholders by reinvesting in Ambrillia", he concluded.

About Mr. Stephen G. Sudovar

Mr. Sudovar is currently CEO of SGS Associates, a health care consulting firm. Mr. Sudovar's career spans 30 years of accomplishments in driving business growth in the health care products and services industry. He held senior management and related cross functional positions at Hoffmann-La Roche from 1988 to 1999, including President of its Roche Laboratories division. During his tenure at Roche Labs, he more than tripled U.S. revenues, consistently increased divisional profit contribution, increased the company's U.S. market share, prepared the organization for the launch of many large products as well as integrated the Syntex and Boehringer Mannheim U.S. operations into Roche. As a member of the Roche Board of Directors and Executive Committee and the Chairman of the Business Operating Committee, he was also responsible for the U.S. business development function and related therapeutic area planning for drug discovery and portfolio management for drug development. During his tenure with Roche, he gained significant global experience as an expatriate in Europe. Mr. Sudovar also headed two successful start-up companies, Pracon Incorporated and Elusys Therapeutics for which he served as President and CEO. Mr. Sudovar is a member of the Board of Nabi Pharmaceuticals and Aastrom Biosciences. He was also Chairman of the National Pharmaceutical Council (NPC) and of the Marketing Section of the Pharmaceutical Research and Manufacturing Association (PhRMA). He holds a B.S. in Marketing from St. Peter's College and an MBA from Fairleigh Dickinson University. He is an Adjunct Professor of Management at Montclair State University.

About Ambrilia Biopharma

Ambrilia Biopharma Inc. (TSX: AMB) is a biopharmaceutical company developing novel small molecules and peptides to treat infectious diseases and cancer. Ambrilia's product portfolio includes promising anti-HIV treatments (PPL-100 and an HIV Integrase Inhibitor Program), two new formulations of existing drugs developed with a patented technology (Octreotide and Goserelin), an anti-cancer therapeutic peptide (PCK3145), a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for a $US 17 million upfront payment, potential milestones that could reach $US 212 million, and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:



view all press releases



Executive Overview

Thirty years of extraordinary accomplishments in driving business growth in the healthcare products and services industry.

view resumePDF icon


  • Board of Directors
  • General Management
  • Strategic Planning
  • Business Development
  • Mergers and Acquisitions
  • Government Affairs view all
michael kors outlet coach factory outlet thunder 14s foamposites for sale Michael Kors Outlet sport blue 3s thunder 14s concord foamposites louis vuitton outlet wolf grey 3s louis vuitton outlet michael kors outlet michael kors outlet louis vuitton outlet Louis Vuitton Outlet Lebron 11 Louis Vuitton Outlet louis vuitton outlet sport blue 6s Michael Kors Outlet